Efficacy and Safety of Tildrakizumab for Treatment of Moderate-to-Severe Scalp Psoriasis in Patients with Obesity Over 52 Weeks - Scorecard - MDSpire

Efficacy and Safety of Tildrakizumab for Treatment of Moderate-to-Severe Scalp Psoriasis in Patients with Obesity Over 52 Weeks

  • By

  • Howard L. Sofen

  • Ranga Gogineni

  • Tushar Nishandar

  • Jerry Bagel

  • May 9, 2026

  • 0 min

Share

Clinical Scorecard: Effectiveness and Safety of Tildrakizumab in Managing Moderate-to-Severe Scalp Psoriasis Among Obese Patients Over a 52-Week Period

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target Population
Care SettingSpecify that it is a clinical trial setting.

Key Highlights

  • add_statistics

Guideline-Based Recommendations

Diagnosis

    Management

    • P
    • r
    • o
    • v
    • i
    • d
    • e
    • d
    • e
    • t
    • a
    • i
    • l
    • e
    • d
    • m
    • a
    • n
    • a
    • g
    • e
    • m
    • e
    • n
    • t
    • s
    • t
    • r
    • a
    • t
    • e
    • g
    • i
    • e
    • s
    • f
    • o
    • r
    • u
    • s
    • i
    • n
    • g
    • t
    • i
    • l
    • d
    • r
    • a
    • k
    • i
    • z
    • u
    • m
    • a
    • b
    • .

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Clinical Best Practices

        • expand_assessment

        References

        Original Source(s)

        Efficacy and Safety of Tildrakizumab for Treatment of Moderate-to-Severe Scalp Psoriasis in Patients with Obesity Over 52 Weeks

        • by Howard L. Sofen, Ranga Gogineni, Tushar Nishandar, Jerry Bagel

        • May 9, 2026

        Related Content

        Guselkumab Shows Psoriasis Benefit in Darker Skin Tones

        Randomized trial suggests sustained clearance across darker skin tones.

        Case Report: rapid progressive puberty in siblings with MC4R p. Arg165Gln: longitudinal follow-up and gonadotropin-releasing hormone agonist treatment

        Envudeucitinib: A Next-Generation Allosteric TYK2 Inhibitor - A Comprehensive Review